Mikrobiomik Healthcare Company S.L.

The company also funds research in hepatology, particularly for non-alcoholic steatohepatitis, a chronic metabolic liver disease marked by inflammation and liver injury. This area places emphasis on liver-related outcomes and disease modification.

• Non-alcoholic steatohepatitis
• Liver inflammation
• Metabolic liver disorder

Its clinical portfolio includes therapies intended to address liver health in patients with steatohepatitis and related metabolic dysfunction.

A central theme in the sponsor’s research is the use of faecal microbiota transfer and intestinal microbiota capsules as therapeutic approaches. This reflects a strong interest in microbiome modulation for both gastrointestinal and liver-related conditions.

• Faecal microbiota transfer
• Microbiome modulation
• Capsule-based microbiota therapy

Research activity in this domain links microbial restoration strategies with disease management in disorders of the gut-liver axis.

The sponsor’s clinical interests extend across the gut-liver axis, where interactions between the intestinal microbiome and hepatic function are relevant to both diverticular disease and steatohepatitis. This connects digestive and liver medicine through microbiome-oriented intervention.

• Gut-liver axis
• Intestinal microbiome
• Hepatic function

The funded studies indicate sustained involvement in therapeutic areas where microbial balance is considered important for gastrointestinal and liver outcomes.